MedTrace Logo

Natural Killer(NK) Cell Therapy in r/r AML

NCT05665114 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-01-03

No results posted yet for this study

Summary

This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in relapse/refractory Acute Myeloid Leukemia (AML).

This clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-030a in patients with r/r AML, where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled.

Conditions

  • AML, Adult

Interventions

DRUG

QN-030a

NK cell therapy

DRUG

Cyclophosphamid

Lympho-conditioning Agent

DRUG

Fludarabine

Lympho-conditioning Agent

DRUG

Cytarabine

Lympho-conditioning Agent

DRUG

VP-16

Lympho-conditioning Agent

Sponsors & Collaborators

  • Hangzhou Qihan Biotech Co.,Ltd.

    collaborator INDUSTRY

  • Zhejiang University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-24
Primary Completion
2023-12-24
Completion
2025-12-24

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05665114 on ClinicalTrials.gov